lactoferrin and Tongue-Neoplasms

To investigate the effect of lactoferrin on vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression.. Lactoferrin at concentration of 0.006, 0.013, 0.025, 0.050 g/L and blank control groups were included in this study. The gene and protein expression of VEGF, bFGF were examined by RT-PCR and Western blotting.. The RT-PCR and Western blotting assay showed that VEGF mRNA(0.31 +/- 0.08) and protein (0.68 +/- 0.11) in lactoferrin (0.050 g/L) group were significantly lower than in the control group (P < 0.05), and the bFGFmRNA (0.27 +/- 0.10) and protein (0.68 +/- 0.07) in lactoferrin (0.050 g/L) group were also significantly lower than in the control group (P < 0.05).. Lactoferrin could inhibit the expression of VEGF, bFGFmRNA and protein in Tca8113 cells. This effect might be one of the mechanisms for anticancer function of lactoferrin.

Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Fibroblast Growth Factor 2; Humans; Lactoferrin; RNA, Messenger; Tongue Neoplasms; Vascular Endothelial Growth Factor A

The modifying effects of dietary feeding of bovine lactoferrin (bLF) on tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide (4-NQO) were investigated in male F344 rats. The activities of phase II detoxifying enzymes, glutathione S-transferase (GST) and quinone reductase (QR), polyamine content and ornithine decarboxylase (ODC) activity in the tongue were also examined for mechanistic analysis of possible modifying effects of bLF on carcinogenesis. At 7 weeks of age, all animals except those treated with bLF alone and untreated rats were given 20 ppm 4-NQO in drinking water for 8 weeks to induce tongue neoplasms. Starting 7 days before 4-NQO exposure, experimental groups were fed experimental diets containing bLF (0.2% and 2%) for 10 weeks ("initiation feeding"). Starting 1 week after the cessation of exposure to 4-NQO, the other experimental groups given 4-NQO and a basal diet were fed the experimental diets for 22 weeks ("postinitiation feeding"). At week 32, the incidence and multiplicity of tongue neoplasms in the "initiation feeding" groups of 0.2% and 2% bLF and the "post-initiation feeding" group of 0.2% bLF were lower than those of the 4-NQO alone group, but without statistical significance. However, "post-initiation feeding" of 2% bLF caused a significant reduction in the incidence (20% vs. 55%, P=0.02418) and multiplicity (0.25+/-0.54 vs. 0.70+/-0.71, P<0.05) of tongue squamous cell carcinoma (by 64%, P=0.02418). bLF treatment elevated liver and tongue GST activities and liver QR activity. The "post-initiation feeding" with 2% bLF significantly decreased QR activity, proliferating cell nulcear antigen-positive index and ODC activity in the tongue. In addition, feeding with bLF decreased tongue polyamine content. These results suggest that bLF, when given at the 2% dose level during the post-initiation phase, exerts chemopreventive action against tongue tumorigenesis through modification of cell proliferation activity and/or the activities of detoxifying enzymes.

Topics: 4-Nitroquinoline-1-oxide; Animals; Body Weight; Carcinogens; Cattle; Epithelium; Glutathione Transferase; Immunohistochemistry; Lactoferrin; Liver; Male; Mucous Membrane; NAD(P)H Dehydrogenase (Quinone); Organ Size; Ornithine Decarboxylase; Precancerous Conditions; Proliferating Cell Nuclear Antigen; Quinolones; Rats; Rats, Inbred F344; Tongue; Tongue Neoplasms

A case of intraductal papilloma occurring in the anterior lingual salivary gland (Blandin-Nuhn's gland) of a 58-year-old woman is presented. This location has not been reported previously. The results of histologic and immunohistochemical studies point to an epithelial origin of excretory salivary gland ducts and also demonstrate the secretory potential of the tumor cells.

Topics: Antigens, Neoplasm; Female; Humans; Immunohistochemistry; Keratins; Lactoferrin; Membrane Glycoproteins; Middle Aged; Mucin-1; Papilloma; S100 Proteins; Salivary Gland Neoplasms; Salivary Glands, Minor; Tongue Neoplasms